Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18;14(1):219.
doi: 10.1038/s41408-024-01200-w.

Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM

Florent Malard  1   2 , Arthur Bobin  3 , Myriam Labopin  4   5 , Lionel Karlin  6 , Laurent Frenzel  7 , Murielle Roussel  8 , Marguerite Vignon  9 , Sophie Godet  10 , Thomas Chalopin  11 , Perrine Moyer  12 , Emilie Chalayer  13 , Frederique Orsini Piocelle  14 , Clara Mariette  15 , Carolyne Croizier  16 , Claudine Sohn  17 , Mamoun Dib  18 , Ronan Le Calloch  19 , Nadia Ali-Ammar  20 , Marion Loirat  21 , Omar Benbrahim  22 , Alexandre Payssot  23 , Adrien Trebouet  24 , Aurore Perrot  25 , Xavier Leleu  3 , Mohamad Mohty  26   27
Affiliations

Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM

Florent Malard et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: F.M. reports honoraria from Therakos/Mallinckrodt, Janssen, Biocodex, Sanofi, JAZZ Pharmaceuticals, Gilead, Novartis, Priothera, and Astellas, all outside the submitted work. L.K. reports honoraria, advisory board participation and travel expenses from Pfizer, Janssen, Takeda, Sanofi and BMS, all outside the submitted work. L.F. reports honoraria from Janssen, Sanofi, Pfizer and Abbvie all outside the submitted work. E.C. reports honoraria for lectures from Sanofi, Janssen, Amgen, Stemline, and for advisory board participation from BMS, Sanofi, Stemline, Pfizer and Janssen, all outside the submitted work. C.C. reports research grants from Abbvie, and Janssen; consulting fees, honoraria, and/or travel funds from Abbvie, Janssen, Sanofi, AstraZeneca, and Novartis, all outside the submitted work. X.L. reports honoraria and consultancy from Janssen. Pfizer. Gilead kite, Novartis, Roche, Takeda, Sanofi, Astra Zeneca, BMS, GSK, Abbvie, and Amgen, all outside the submitted work. A.P. reports honoraria from Abbvie, Amgen, Janssen, GSK, BMS, Sanofi, Pfizer and Takeda, all outside the submitted work. M.M. reports grants and honoraria from Janssen, Sanofi, and JAZZ Pharmaceuticals, honoraria from Celgene, Amgen, MaaT Pharma, BMS, Takeda, and Pfizer, and grants from Roche, all outside the submitted work. The other authors did not disclose any relevant conflict of interest.

Figures

Fig. 1
Fig. 1. Real-world clinical outcomes with elranatamab.
A Duration of response; (B) Time to next treatment.
See this image and copyright information in PMC

References

    1. Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570–6. 10.1038/s41591-023-02589-w. - PMC - PubMed
    1. Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45. 10.1038/s41572-024-00529-7. - PubMed
    1. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259–67. 10.1038/s41591-023-02528-9. - PMC - PubMed
    1. Afram G, Gran C, Borg Bruchfeld J, Wagner AK, Hussain A, Alici E, et al. Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment. Eur J Haematol. 2020;105:196–202. 10.1111/ejh.13426. - PubMed
    1. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen W-M, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224–33. 10.1038/s41375-019-0539-0. - PMC - PubMed

LinkOut - more resources